A Virtual Reality-Assisted Cognitive Behavioral Therapy for and With Inuit in Québec: Protocol for a Proof-of-Concept Randomized Controlled Trial.
Indigenous
Inuit health
biofeedback
co-design
cognitive behavioral therapy
cultural adaptation
emotion regulation
randomized controlled trial
virtual reality
Journal
JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504
Informations de publication
Date de publication:
24 May 2023
24 May 2023
Historique:
received:
14
06
2022
accepted:
10
01
2023
revised:
19
12
2022
medline:
24
5
2023
pubmed:
24
5
2023
entrez:
24
5
2023
Statut:
epublish
Résumé
Emotion regulation is an ability related to psychological well-being; when dysregulated, individuals may have psychiatric symptoms and maladapted physiological responses. Virtual reality-assisted cognitive behavioral therapy (VR-CBT) is an effective psychotherapy to target and strengthen emotion regulation; however, it currently lacks cultural sensitivity and can be improved by adapting it to the cultural context of service users. During previous participatory research, we co-designed a culturally adapted cognitive behavioral therapy (CBT) manual and 2 virtual reality (VR) environments to function as a complement to therapy (VR-CBT) for Inuit who would like to access psychotherapy. Emotion regulation skill building will occur in virtual environments that have interactive components such as heart rate biofeedback. We describe a protocol for a proof-of-concept 2-arm randomized controlled trial (RCT) with Inuit (n=40) in Québec. The primary aims of this research are to investigate the feasibility, benefits, and challenges of the culturally adapted VR-CBT intervention versus an established VR self-management that is available commercially. We will also investigate self-rated mental well-being and objective psychophysiological measures. Finally, we will use proof-of-concept data to identify suitable primary outcome measures, conduct power calculations in a larger trial for efficacy, and collect information about preferences for on-site or at-home treatment. Trial participants will be randomly assigned to an active condition or active control condition in a 1:1 ratio. Inuit aged 14 to 60 years will receive a culturally adapted and therapist-guided VR-CBT with biofeedback or a VR relaxation program with nonpersonalized guided components over a 10-week period. We will collect pre- and posttreatment measures of emotion regulation and biweekly assessments over the treatment and at 3-month follow-up. The primary outcome will be measured by the Difficulties in Emotion Regulation Scale (DERS-16) and a novel psychophysiological reactivity paradigm. Secondary measures include psychological symptoms and well-being via rating scales (eg, anxiety or depressive symptoms). As this is the prospective registration of an RCT protocol, we do not yet report any results from the trial. Funding was confirmed in January 2020, and recruitment is expected to start in March 2023 and is set to finish in August 2025. The expected results are to be published in spring 2026. The proposed study responds to the community's desire for accessible and appropriate resources for psychological well-being, as it was developed in active collaboration with the Inuit community in Québec. We will test feasibility and acceptance by comparing a culturally adapted, on-site psychotherapy with a commercial self-management program while incorporating novel technology and measurement in the area of Indigenous health. We also aim to fulfill the needs for RCT evidence of culturally adapted psychotherapies that are lacking in Canada. International Standard Randomized Controlled Trial Number (ISRCTN) 21831510; https://www.isrctn.com/ISRCTN21831510. PRR1-10.2196/40236.
Sections du résumé
BACKGROUND
BACKGROUND
Emotion regulation is an ability related to psychological well-being; when dysregulated, individuals may have psychiatric symptoms and maladapted physiological responses. Virtual reality-assisted cognitive behavioral therapy (VR-CBT) is an effective psychotherapy to target and strengthen emotion regulation; however, it currently lacks cultural sensitivity and can be improved by adapting it to the cultural context of service users. During previous participatory research, we co-designed a culturally adapted cognitive behavioral therapy (CBT) manual and 2 virtual reality (VR) environments to function as a complement to therapy (VR-CBT) for Inuit who would like to access psychotherapy. Emotion regulation skill building will occur in virtual environments that have interactive components such as heart rate biofeedback.
OBJECTIVE
OBJECTIVE
We describe a protocol for a proof-of-concept 2-arm randomized controlled trial (RCT) with Inuit (n=40) in Québec. The primary aims of this research are to investigate the feasibility, benefits, and challenges of the culturally adapted VR-CBT intervention versus an established VR self-management that is available commercially. We will also investigate self-rated mental well-being and objective psychophysiological measures. Finally, we will use proof-of-concept data to identify suitable primary outcome measures, conduct power calculations in a larger trial for efficacy, and collect information about preferences for on-site or at-home treatment.
METHODS
METHODS
Trial participants will be randomly assigned to an active condition or active control condition in a 1:1 ratio. Inuit aged 14 to 60 years will receive a culturally adapted and therapist-guided VR-CBT with biofeedback or a VR relaxation program with nonpersonalized guided components over a 10-week period. We will collect pre- and posttreatment measures of emotion regulation and biweekly assessments over the treatment and at 3-month follow-up. The primary outcome will be measured by the Difficulties in Emotion Regulation Scale (DERS-16) and a novel psychophysiological reactivity paradigm. Secondary measures include psychological symptoms and well-being via rating scales (eg, anxiety or depressive symptoms).
RESULTS
RESULTS
As this is the prospective registration of an RCT protocol, we do not yet report any results from the trial. Funding was confirmed in January 2020, and recruitment is expected to start in March 2023 and is set to finish in August 2025. The expected results are to be published in spring 2026.
CONCLUSIONS
CONCLUSIONS
The proposed study responds to the community's desire for accessible and appropriate resources for psychological well-being, as it was developed in active collaboration with the Inuit community in Québec. We will test feasibility and acceptance by comparing a culturally adapted, on-site psychotherapy with a commercial self-management program while incorporating novel technology and measurement in the area of Indigenous health. We also aim to fulfill the needs for RCT evidence of culturally adapted psychotherapies that are lacking in Canada.
TRIAL REGISTRATION
BACKGROUND
International Standard Randomized Controlled Trial Number (ISRCTN) 21831510; https://www.isrctn.com/ISRCTN21831510.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)
UNASSIGNED
PRR1-10.2196/40236.
Identifiants
pubmed: 37223973
pii: v12i1e40236
doi: 10.2196/40236
pmc: PMC10248771
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e40236Informations de copyright
©Quinta Seon, Noor Mady, Michelle Yang, Maharshee Karia, Myrna Lashley, Claudia Sescu, Maud Lalonde, Stephen Puskas, Joy Outerbridge, Echo Parent-Racine, Catherine Pagiatakis, Liliana Gomez-Cardona, Di Jiang, Stéphane Bouchard, Outi Linnaranta. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 24.05.2023.
Références
Addict Sci Clin Pract. 2017 Jan 4;12(1):2
pubmed: 28049515
Eur Child Adolesc Psychiatry. 2021 Jun;30(6):829-848
pubmed: 32108914
J Hypertens. 2003 Nov;21(11):1983-92
pubmed: 14597836
J Anxiety Disord. 2019 Jan;61:27-36
pubmed: 30287083
J Affect Disord. 2021 Jan 1;278:296-310
pubmed: 32979561
Health Qual Life Outcomes. 2009 Feb 19;7:15
pubmed: 19228398
Compr Psychiatry. 2020 Oct;102:152189
pubmed: 32629064
Curr Psychiatry Rep. 2019 Jul 1;21(8):68
pubmed: 31263971
BMC Psychiatry. 2017 Dec 28;17(1):411
pubmed: 29282024
JAMA Netw Open. 2020 Sep 1;3(9):e2015707
pubmed: 32880649
Front Psychol. 2019 Jun 18;10:1261
pubmed: 31275191
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Occup Med (Lond). 2012 Dec;62(8):600-5
pubmed: 22965867
Emotion. 2020 Feb;20(1):37-42
pubmed: 31961175
Epilepsy Behav. 2016 Apr;57(Pt A):211-216
pubmed: 26994447
Arch Intern Med. 1998 Sep 14;158(16):1789-95
pubmed: 9738608
J Pers Assess. 2016;98(3):298-309
pubmed: 26538407
Gen Hosp Psychiatry. 2016 Mar-Apr;39:24-31
pubmed: 26719105
JMIR Mhealth Uhealth. 2019 Oct 7;7(10):e14877
pubmed: 31593537
Psychiatry Res. 2019 Jan;271:230-238
pubmed: 30502560
Clin Psychol Rev. 2010 Mar;30(2):217-37
pubmed: 20015584
Front Psychol. 2018 Apr 19;9:539
pubmed: 29725312
J Affect Disord. 2019 Jul 1;254:59-68
pubmed: 31108281
Sensors (Basel). 2020 Jan 15;20(2):
pubmed: 31952141
J Subst Abuse Treat. 2007 Mar;32(2):189-98
pubmed: 17306727
Aust N Z J Psychiatry. 2016 Nov;50(11):1040-1054
pubmed: 27514405
J Psychopathol Behav Assess. 2016 Jun;38(2):284-296
pubmed: 27239096
J Gen Intern Med. 2016 Oct;31(10):1206-11
pubmed: 27170304
Health Qual Life Outcomes. 2016 Sep 08;14(1):126
pubmed: 27608769
JAMA Psychiatry. 2020 Sep 1;77(9):925-935
pubmed: 32401284
Neuropsychiatr Dis Treat. 2018 Jan 04;14:165-178
pubmed: 29379289
J Behav Ther Exp Psychiatry. 2014 Dec;45(4):447-53
pubmed: 24978117
Can J Public Health. 2018 Dec;109(5-6):662-670
pubmed: 30302729
Front Psychiatry. 2020 Jul 14;11:671
pubmed: 32765315
Int J Methods Psychiatr Res. 2013 Jun;22(2):138-43
pubmed: 23670783
Internet Interv. 2021 Feb 02;24:100370
pubmed: 33665136
JAMA. 2020 Jun 9;323(22):2290-2300
pubmed: 32515813
Rheumatol Int. 1985;5(4):145-8
pubmed: 4048757
Psychol Assess. 2015 Sep;27(3):944-54
pubmed: 25774638
Int J Psychophysiol. 2021 Jan;159:94-106
pubmed: 33248196
Trends Psychiatry Psychother. 2020 Jan-Mar;42(1):30-38
pubmed: 32321083
Addict Behav. 1982;7(4):363-71
pubmed: 7183189
Front Psychol. 2019 Feb 04;10:132
pubmed: 30778311
Clin Psychol Rev. 2017 Nov;57:141-163
pubmed: 28941927
Clin Psychol Rev. 2019 Aug;72:101751
pubmed: 31271848
SAGE Open Med. 2020 Feb 07;8:2050312120906042
pubmed: 32095239
Health Qual Life Outcomes. 2007 Nov 27;5:63
pubmed: 18042300
J Pers Assess. 2019 Nov-Dec;101(6):598-608
pubmed: 30142305
Behav Res Methods. 2008 Aug;40(3):699-704
pubmed: 18697664
Drug Alcohol Depend. 2006 Jun 9;83(1):90-3
pubmed: 16310973
Alcohol Clin Exp Res. 2005 Nov;29(11):2001-7
pubmed: 16340457
Front Psychol. 2019 Dec 11;10:2763
pubmed: 31920816
Br J Psychiatry. 2002 Jan;180:51-60
pubmed: 11772852
J Clin Psychol. 2012 Sep;68(9):989-1007
pubmed: 22653763
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
J Psychopathol Behav Assess. 2017 Mar;39(1):140-146
pubmed: 28260835
J Clin Med. 2020 Feb 12;9(2):
pubmed: 32059514
J Am Coll Health. 2021 Nov-Dec;69(8):872-880
pubmed: 31995461
J Child Adolesc Trauma. 2016 Oct 28;11(2):173-186
pubmed: 32318148